#United States #Southlake #Renibus Therapeutics #RBT-1 #Veverimer

Renibus Therapeutics at the Oppenheimer Life Sciences Conference

Renibus Therapeutics, a clinical-stage biopharmaceutical firm specializing in the prevention and treatment of cardiac, renal, and metabolic diseases, is making headlines as it announces its participation in the 36th Annual Oppenheimer Life Sciences Conference. Scheduled for February 25-26, 2026, the conference will provide a platform for significant discussions around the company’s innovative therapies and advancements in the biomedical field.

Presentation Details

The spotlight will be on Dr. Bhupinder Singh, Chief Medical Officer at Renibus, who is set to deliver a presentation virtually on February 25 at 2:40 PM Eastern Standard Time. This session will delve into the company’s strategic initiatives and research developments that focus on improving patient outcomes in chronic diseases.

In addition to the presentation, Renibus management will engage in one-on-one meetings with investors, offering an opportunity to discuss the company’s trajectory and future direction.

About Renibus Therapeutics

Founded with the mission to combat complex health challenges, Renibus Therapeutics has made significant strides in the biopharmaceutical landscape. The firm’s lead therapeutic candidate, veverimer, is currently advancing to Phase 3 clinical trials. This innovative agent is designed to treat metabolic acidosis in adults with chronic kidney disease, addressing a critical unmet need in this patient population.

Renibus is also progressing with its second late-stage program, RBT-1, which recently concluded the PROTECT Phase 3 trial aimed at patients undergoing cardiac surgery. The trial outcomes suggest promising potential for further development, particularly in patients exhibiting higher risk factors, a finding that Renibus is currently evaluating.

The Importance of the Oppenheimer Conference

The Oppenheimer Life Sciences Conference is a crucial event that gathers experts, investors, and innovators in the life sciences field. Participation in such conferences allows companies like Renibus to showcase their advancements, connect with potential investors, and engage in discussions that can influence the future of healthcare.

For those interested in the ongoing development of treatments for serious conditions, Renibus Therapeutics’ participation in this conference is highly anticipated, as it reflects the company’s commitment to transparency and innovation.

Engaging with Renibus Therapeutics

For more details on Renibus Therapeutics and its endeavors in advancing biopharmaceutical solutions, you can visit their official website at Renibus.com. In addition, they encourage connections on LinkedIn, where updates about their projects, partnerships, and research can be accessed.

Contacts

For any media inquiries or for more information about their products, Renibus has specified contacts as follows:

• - Media Contact: Amy Conrad, Juniper Point, Email: [email protected], Phone: 858-914-1962
• - Business Development Contact: Jamie Donadio, CFO, Renibus, Email: [email protected]

As the healthcare industry continually evolves, events like the Oppenheimer Life Sciences Conference are essential for companies like Renibus to share their progress and engage with stakeholders poised to make a difference in patient care.